Retatrutide in Australia: TGA Status, Trial Research and Research Supply

Is Retatrutide Available in Australia? The Short Answer

In Australia, retatrutide is not approved by the TGA for human use, is not listed on the Australian Register of Therapeutic Goods, and is not available through pharmacies, prescription or compounding. It remains an investigational compound still in clinical trials. At NovaPeptides it is supplied strictly for research use only, not for human consumption. This page is general information, not legal or medical advice.

That single paragraph answers the question most Australians are actually asking when they search "retatrutide australia": can I get it, is it legal, and what is it. The honest position is that retatrutide is one of the most closely watched compounds in metabolic research, and it is also one that no Australian can legally obtain as a medicine, because it has not finished the trials that approval depends on. Everything below explains that situation in full, sets out what the published research has studied, and describes how the compound is supplied to researchers without quoting prices or making therapeutic claims.

What Is Retatrutide? The Triple Agonist (LY3437943) Explained

Retatrutide is an investigational once-weekly injectable peptide developed by Eli Lilly under the code LY3437943, and informally called Reta or the Triple G. It is described as a first-in-class triple hormone-receptor agonist, which means a single molecule activates three separate metabolic receptors at the same time: GLP-1, GIP and glucagon. That triple action is the headline reason it draws so much research attention.

The triple mechanism is also the cleanest way to understand how retatrutide differs from the GLP-class compounds that came before it. Semaglutide is a single agonist that engages the GLP-1 receptor alone. Tirzepatide is a dual agonist that adds the GIP receptor. Retatrutide goes one step further and adds the glucagon receptor, which is studied for its role in energy expenditure. There is no completed head-to-head trial directly comparing retatrutide against tirzepatide, so any comparison stays strictly at the level of receptor count and what each compound has been studied for, never a claim that one is better than another.

At NovaPeptides the compound is supplied as a lyophilised, or freeze-dried, research powder within the kit designated RT60. The names retatrutide, LY3437943, Triple G and RT60 all refer to the same molecule. RT60 is simply the NovaPeptides kit designation for the research material, supplied for research use only.

Retatrutide and the TGA: Regulatory Status in Australia

The regulatory picture is clear and worth stating without hedging. As verified in June 2026, retatrutide is not approved by the Therapeutic Goods Administration, is not entered on the Australian Register of Therapeutic Goods, and cannot be prescribed, dispensed or compounded as a medicine in Australia. It is an investigational compound, which means it is still being tested in clinical trials and has not completed the process that approval requires.

What the status means in practice

• Not TGA-approved for human use and not on the ARTG.
• Not available by prescription, from a pharmacy, or through a compounding chemist.
• Still an investigational compound inside Eli Lilly's ongoing clinical trial program.
• At NovaPeptides, supplied for research use only and not for human consumption.
• Any future approval timeline is uncertain and should not be assumed.

It is also worth being honest about timelines, because this is where speculation tends to fill the gap. Retatrutide remains an investigational compound in ongoing trials. Any future Australian approval is uncertain, is not guaranteed, and no timeline should be assumed. This is general information, not legal advice.

What the Trials Have Studied: TRIUMPH and the Published Data

Retatrutide sits inside Eli Lilly's Phase 3 TRIUMPH program, an umbrella of pivotal trials plus a large cardiovascular outcomes study, spanning weight-management and diabetes indications. The figures below are drawn from peer-reviewed publications. They describe what was observed in specific trial populations and are presented strictly as research findings, never as outcomes any reader should expect.

Retatrutide has been studied in published Phase 2 obesity trial research (Jastreboff et al., New England Journal of Medicine, 2023, in adults with obesity over 48 weeks), where it was investigated for dose-dependent effects on body weight over the study period. The specific trial figures sit in the primary scientific literature. We do not reproduce them here as outcome figures, because retatrutide is investigational, is supplied for research use only, and individual results are never promised.

A separate Phase 2a trial published in Nature Medicine in 2024 examined liver fat in a metabolic-dysfunction-associated steatotic liver disease (MASLD) research context. As with the weight research, the detailed numbers belong to the primary literature and are not presented here as outcomes. The point for a research audience is simply that retatrutide is an active subject of late-stage metabolic research, not an approved therapy.

More recently, the Phase 3 TRIUMPH-1 trial in adults with obesity or overweight without diabetes reported positive topline weight-reduction results in 2026. These are reported topline findings from a press release rather than a full peer-reviewed publication, and no numeric result should be assumed until the complete data is published. They describe the trial population, not any individual reader.

On safety, the trials reported that the most common adverse events were gastrointestinal: nausea, vomiting, diarrhoea and constipation, generally mild to moderate and mostly during dose escalation. Dose-dependent heart-rate increases were observed early before declining. This is investigational safety data from a trial setting, not a safety guarantee and not advice.

Cost, Access and Research Supply: How Retatrutide Is Supplied

Many people who search for retatrutide in Australia are really asking about cost and access. The honest answer is that there is no approved retatrutide medicine to price, because it is not available for personal or therapeutic use anywhere in the country. What does exist is a research-supply context, and that is the only context NovaPeptides operates in. We do not quote prices, run a cart, or compare against pharmacy medicines, because doing so would misrepresent what this compound is.

For researchers, retatrutide is supplied as a lyophilised powder within the RT60 research kit. Rather than a loose vial, the kit is assembled as a complete research set, and every batch is backed by an independent Certificate of Analysis. The differentiators that matter here are verifiability and logistics, not price.

What the research-supply context looks like

• Supplied as a lyophilised (freeze-dried) powder for laboratory and in-vitro research use only.
• Provided as the complete RT60 research kit rather than a loose vial.
• Backed by an independent Janoshik Certificate of Analysis, available on request.
• Australian shipping, handled within a research-use-only framework.
• Enquiries handled by WhatsApp rather than a checkout, with no displayed price.

Quality and Verification: The Independent Janoshik COA

For a research compound, the single most useful trust signal is independent lab verification, because purity is something to be checked rather than taken on faith. The retatrutide supplied by NovaPeptides is tested by Janoshik, the third-party analytical lab the peptide research community treats as a reference standard for identity and purity verification by HPLC.

99.8%

The point of an independent COA is verifiability, not decoration. Rather than asking anyone to trust a number printed on a page, the report itself is the evidence. You can request the actual Janoshik certificate, read the identity and purity figures in black and white, and confirm them against the lab's own records. A research result is only as trustworthy as the material behind it, and a verifiable certificate is how that trust is earned rather than asserted.

Frequently asked questions